Heart disease, diabetes can be fatal combination

heartThe combination of type 2 diabetes and disease of the coronary arteries can be fatal, according to a new study that found that patients with type 2 diabetes admitted to hospital for heart failure have a one in four chance of dying in the next 18 months .

The findings show a much bleaker picture of the evolution of diabetic patients with severe heart disease than previously known, the researchers said. “2 diabetes accompanied by acute coronary syndrome type needs much more attention, especially in order to prevent another major cardiac event,” said William B White of the University of Connecticut in the US ..

Patients with type 2 diabetes are two to three times the risk of heart disease in the general population. This is partly due to obesity and other diseases such as
hypertension and high cholesterol levels contribute to both diseases, but there is concern that some of the medications that help control blood sugar can also damage the heart, the researchers said.

Even insulin, a hormone that healthy people do naturally, but some patients with type 2 diabetes often need as a drug, can contribute to heart disease, they said. White, along with their colleagues in 898 medical institutions around the world tested alogliptin diabetes drug that is a member of the family of drugs known as DPP-4.

The researchers recruited 5,380 patients with type 2 diabetes after the patient had a major acute coronary syndrome, but not fatal, as a heart attack, or hospitalization for unstable angina. randomize patients to take either alogliptin or placebo, and then followed their progress for up to three years were assigned.

The study results showed no difference for alogliptin versus placebo patients in the primary endpoint of cardiovascular death, myocardial infarction or stroke. Now researchers provide new insights into mortality in the trial of a series of new analyzes. People with type 2 diabetes admitted to hospital for heart failure faced a 24 to 28 percent probability of death during the rest of the trial, aloglipin or placebo, respectively, the researchers said.

That’s more than five times the risk of death was seen in patients who had additional cardiovascular event not fatal, while in the study, said.

The researchers found that patients with type 2 diabetes admitted to hospital for congestive heart failure face a one in four chance of dying in the next 18 months. “It’s a very dramatic result. A person with type 2 diabetes who require hospitalization for heart failure in diabetes trial was a harbinger of a very poor outcome,” White said. The findings were published in the journal Diabetes Care.

Comments

comments